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Abstract 
Giovanna Rappocciolo, PhD 
 
Identification of Circulating Biomarkers of HIV Disease Progression 
 
Katrina M. Stephenson, MS 
 
University of Pittsburgh, 2020 
 
Abstract 
 Understanding the ability of Nonprogressors (NP)  to control HIV disease progression may 
lead to novel therapeutic strategies and vaccines, with the potential to make a significant 
contribution to the field of public health. A small percentage of HIV infected individuals control 
HIV disease progression for many years without therapeutic intervention, defined as long-term 
nonprogressors (NP). We have demonstrated that all professional antigen presenting cells (APC) 
(B cells, dendritic cells (DC) and macrophages) from NP have the unique inability to mediate HIV 
trans infection of autologous and heterologous CD4+T cells. We have linked this phenotype to 
alterations in cholesterol metabolism in APC, specifically an increased activity of the reverse 
cholesterol transporter ABCA-1, and to depletion of cholesterol in cell membrane lipid rafts. 
ABCA1 activity could be modulated by transcriptional or post transcriptional factors. Our data 
show that plasma from NP elicit higher cholesterol efflux from macrophages in males and females 
than Progressors (PR).  
It was also our aim to identify soluble, circulating biomarkers that could modulate ABCA1 
activity, thus being associated with control of HIV disease progression. A bioactive fatty acid 
screen was performed on a subset of NP and PR samples that have been well-characterized by 
testing for APC mediated trans infection. Analysis by liquid-chromatography-mass 
spectrophotometry identified metabolites present at a higher level in NP than PR, specifically 5-
oxo-eicosatetranoic acid (5-Oxo-ETE). Preliminary data of 5-oxo show that treatment of APC at 
 v 
5µM reduces the efficiency of HIV trans infection of CD4+T cells. A second molecule that was 
tested was 25-Hydroxycholesterol (25HC), which interferes with virus-cell membrane fusion and 
reduces inflammatory factors and cytokines. Serum from HIV infected individuals was tested for 
25HC content by ELISA, and preliminary data show that 25HC levels are slightly higher in NP 
than PR, but more samples need to be analyzed. A trans infection assay in the presence of 25HC 
was also performed and it was found that treatment of B cells with 25HC in culture strongly 
inhibits HIV trans infection.  
Genetic factors have been identified that contribute to cholesterol efflux capacity in men 
and women. SNPs were identified by Villard et.al. that affect the ability of macrophages to efflux 
cholesterol and were implicated in atherosclerotic development. These SNPs were tested in our 
HIV NP and PR cohorts. Two SNPs were found to be significantly associated with the male NP, 
contributing to differences in cholesterol metabolism and homeostasis in male and female NP and 
PR.  
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1.0 Introduction 
The Human Immunodeficiency virus (HIV) is a positive-sense retrovirus with a double 
membrane derived from the host cell. The viral envelope contains two major glycoproteins, gp41 
and gp120, which mediate viral entry and fusion. Viral RNA is enclosed by a capsid core composed 
of three structural proteins, p24, p16 and p9 (1). The p24 protein encloses the genomic viral RNA 
and enzymes required for replication. After entry into the cytoplasm, the capsid disintegrates, and 
the viral RNA is reverse transcribed into DNA where it is transported to the nucleus. The HIV 
protein, integrase, then incorporates the viral DNA into the host chromosome. The viral DNA is 
replicated with the host DNA to make progeny genomes and transcribe viral proteins for assembly 
into new viral particles at the cellular membrane (1). High content of cellular lipid rafts is desirable 
for virion assembly (3). A lipid raft is an area of the host membrane that contains high cholesterol 
and sphingolipid content, and is involved in signal transduction, and endocytosis (2). They are 
required at multiple points in the viral life cycle and server as docking sites for entry receptors and 
anchor viral glycoproteins during assembly (2).  
HIV primarily infects CD4+ T cells through the CD4 molecule and either the C-C 
chemokine receptor type 5 (CCR5) or C-X-C chemokine receptor type 4 (CXCR4) coreceptors. 
There are two strains of the virus: T-cell-tropic (T-tropic) and macrophage-tropic (M-tropic) (4). 
T-tropic virus uses the CXCR4 coreceptor more commonly expressed on CD4+ T cells and M-
tropic use CCR5 as a coreceptor (1). The virus is also able to infect monocytes, such as dendritic 
cells, B cells and macrophages though these chemokine receptors as well as DC-SIGN (5).  
HIV has infected 75 million people since the epidemic first began and has killed 32 million 
globally (6). An estimated 38 million are currently living with the disease, and it affects 
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approximately 0.8% of people age 15-49 globally (7). Since the beginning of the epidemic in the 
1980s, new HIV infections have been reduced from 130,000 to 50,000 in 2010 (8). The prevalence 
of people living with the disease has greatly increased due to treatment advances and the 
development of antiretroviral therapy (ART), which dramatically reduced the number of deaths 
from HIV. ART therapy reduces viral load in plasma to undetectable levels inhibiting the virus at 
different stages of replication, including attachment, fusion, reverse transcription and integration 
of the virus. Currently there is no cure or vaccine for HIV and the virus cannot be fully eradicated 
from the body. 
1.1 HIV Long-term Nonprogressors 
Several years after the emergence of HIV, a small group of infected individuals were found 
to have slow progression to AIDS and were referred to as Long-Term Nonprogressors (LTNP) (9). 
Progression from HIV to AIDS can largely be divided into three categories: rapid progression, 
where AIDS is developed within three years of infection; intermediate progression, where AIDS 
develops slowly between three and 10 years; and long-term nonprogression (LTNP), where 
individuals maintain high CD4+ and CD8+ T cell counts for more than 8 years without anti-
retroviral therapy (10). LTNP comprise a small percentage of HIV infected individuals are able to 
control disease progression for many years without therapeutic intervention, maintaining high 
CD4+ cell counts and, in most cases, detectable viral loads (Figure 1). These individuals represent 
less than 5% of the HIV infected population and can be divided into three categories: (i) long-term 
nonprogressors, who have high CD4+ cell counts with detectable viral loads; (ii) viremic 
controllers (VC), who have high CD4+ cell count and high viral loads (>2000 RNA copies/mL), 
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and (iii) elite controllers (EC), who have no detectable viral load though it is known they have 
been exposed to the virus. There are several viral, immunological and genetic factors that 
contribute to HIV-1 nonprogression, but not one of these are present in all NP and are unable to 
completely explain the phenomenon.  
 
 
 
 
 
 
 
 
Figure 1. HIV Nonprogressors 
HIV nonprogressors maintain high CD4+ counts and have detectable viremia compared to normal progressors and 
rapid progressors (Poropatich and Sullivan, 2011). 
 
1.1.1 Factors Contributing to Nonprogression 
There are host, genetic and viral factors that may influence the rate of progression to AIDS. 
Below are some common and well-known elements that contribute to HIV nonprogression. 
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1.1.1.1 Viral Attenuation 
Studies have shown that viruses of HIV nonprogressors have lower diversity than 
progressors, diversity of quasispecies being hallmark feature of HIV infection. They also show 
higher replication incompetence of the virus, including stop codons in structural genes and missing 
long-term repeats (11). Decreased viral evolution correlates with weaker viral fitness and inability 
to evade the immune system. It has been shown that in many cases viruses from LTNP infect CD4+ 
monocytes less efficiently and more slowly in culture (12).  
1.1.1.2 Chemokine Receptor Polymorphism CCR5-Delta32 
CCR5 is normally expressed at low levels on CD4+ cells. Studies have shown that some 
NP have an allele with a mutation in this gene consisting of a 32 base pair deletion that introduces 
a stop codon that truncates the protein rendering it ineffective. Studies have shown that NP are 
more frequently heterozygous for this allele than progressors, but there has been conflicting data 
regarding the significance of this polymorphism with the control of HIV infection (13). Many 
newer studies have reported it absent in their LTNP cohorts, whereas some older studies reported 
this to be highly a significant factor contributing to the control of the disease (13). 
1.1.1.3 HLA Class I Alleles 
HLA Class I Alleles (A, B and C) present antigens to CD8+ T cells to control HIV 
replication. People who are heterozygous have been shown to slow HIV progression due to 
presentation of a larger pool of peptides, decreasing viral escape and immune evasion (14). Two 
HLA-B57 variants have been linked to HIV control, B5701 and B5703, by inducing a strong 
response against the GAG protein (15). HLA-B27 has also been linked to nonprogression by 
producing a strong CTL response to the p24 capsid protein, but is found to be ubiquitous in the 
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human population (16). Between 1 and 10% of humans carry a copy of the HLA-B57 allele and 
1.8-8% carries a copy of HLA-B27. They have been found to vary considerably in NP cohorts 
anywhere from 2-63% (13). 
1.1.1.4 APOBEC3G 
APOBEC3G is a cytidine deaminase that stops HIV from integrating by introducing G to 
A base mutations in viral DNA producing premature stop codons, causing the virus to become 
replication incompetent (14). Higher levels of APOBEC3G have been associated with higher CD4+ 
cell counts and lower viral loads. People with lower viral loads, who had been infected for three 
years or more, had higher levels of APOBEC3G than progressors or seronegative controls (17).  
1.1.1.5 CD8+ T cells 
CD8+ T cells are important in killing HIV infected cells and lowering viremia. It has been 
shown that NPs have a more broadly effective CTL response against the env, gag and pol proteins 
compared to PR (18). An inverse correlation has been found between the number of gag epitopes 
recognized by CTLs and viral load. Regions of the protein have been identified that most strongly 
correspond with lower viral load and higher CD4+ cell count (19). Studies have also shown that 
quantatively, CTL response between NP and PR are largely the same, but differ based on 
proliferation, cytotoxicity and production of IFN-y, IL-2 and granzyme B (20). CTLs of NP were 
also found to be highly functional, having four or five functions compared to two or three in PR 
(20). CD8+ cells of NP secrete more Granzyme B and perforin on average, required for cytolysis 
of infected cells (21). 
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1.1.1.6 CD4+ T Cells 
HIV-specific CD4+ T cell counts correlate to higher CD8+ counts and lower viral loads 
(22).  Similar to CD8+ T cells, the CD4+ cells of NP have been found to have a broadly robust 
defense against the gag protein, and this remains at high levels throughout the duration of their 
disease, correlating to lower viral load (23). NP have been found to have higher levels of CD4+IL-
2+IFN-γ + cells, with larger production of IL-2, skewing the response toward inflammatory Th1 
(24). There is some data showing that CD4+ T cells of NP are chronically activated based on their 
increased HLA-DR expression, increased IFN-y production and decrease in IL-7a, and this is 
different from non-specific CD4+ activation in PR (24). IL-7 is important for T cell proliferation 
and it’s receptor, IL-7R, has been found to be expressed at highler levels in NP compared to PR, 
helping with thymic replenishment of depleted peripheral CD4+ T cells (25). 
1.1.1.7 Pro- and Anti-Inflammatory Cells 
HIV-infected individuals have been found to have higher levels regulatory T cells (Treg), 
a type of CD4+, compared to uninfected controls (26). Tregs are able to downregulate chronic 
immune activation and lower unspecific immune responses, which can be beneficial to the host. 
Tregs are found at higher levels in PR compared to NP and uninfected controls, and this may 
actually be harmful by downregulating the response to the virus too strongly to appropriately fight 
the infection (27). Th17 cells have an opposing function to Tregs and create an inflammatory 
response, playing an important role in eliminating extracellular pathogens. Together Tregs and 
Th17 keep the immune system in check. In normal progressors, this balance is off and Th17 
response is weakened, while the Treg response is strengthened. In NP the balance remains intact 
and is more similar to the uninfected population (28).   
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1.2 Latency and Reservoirs 
Treatment of HIV with antiviral therapy (ART) has dramatically reduced the death rate 
from HIV/AIDS, but it is not able to completely eradicate the virus from the body. Soon after 
infection, HIV forms a latent reservoir in a small population of long-lived resting CD4+ memory 
cells where it is maintained when active cells revert back to their resting state. They can live for 
many years and replicate at low levels while carrying integrated viral genomes, with little to no 
viral gene expression occurring (29). HIV also forms a reservoir in cells of the 
monocyte/macrophage lineage that support low-level replication of the virus. All of these cell 
types can produce infectious virus when reactivated or during interruptions in ART, and 
disruptions of treatment causes a rapid rebound in viremia. 
1.3 APC-Mediated HIV Trans Infection 
HIV-1 infection can occur through two mechanisms: cis and trans. In cis infection, the 
virus enters through the CD4 molecule and a coreceptor CXCR4 or CCR5, which forms the entry 
receptor complex for the virus. The complex binds viral glycoproteins gp120 and gp41, causing 
fusion of the viral envelope and the cell membrane and release of the capsid into the cytoplasm 
(30). The virus then goes through its normal life cycle of, integration, assembly and budding to 
form infectious progeny virus. Trans infection most commonly occurs between an APC and CD4+ 
T cell. In trans infection, the virus uses an alternate receptor, DC-SIGN, and is endocytosed into 
a non-degrading compartment where it is held for up to 3 days (30). When the APC comes into 
contact with a CD4+ T cell, the virus causes upregulation of HIV receptors CD4, CXCR4 and 
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CCR5 on the T cell (31). This forms the infectious synapse, a structure similar to the 
immunological synapse but orchestrated by the virus. An intact virion is then passed from the APC 
to CD4+ T cell. This causes a burst of viral production from the CD4+ T cell that is much greater 
than cis or trans infection between T cells (30). 
HIV Nonprogressors  have been characterized by the inability of their professional antigen 
presenting cells (APC) to mediate HIV trans infection to autologous CD4+ T cells (Figure 2). The 
inability of the NP phenotype to trans infect CD4+ T cells has been linked to altered cholesterol 
metabolism in APC, increase in reverse cholesterol transporter ATP-binding cassette transporter 
1 (ABCA1) activity and depletion of cholesterol in membrane lipid rafts (Figure 3) (32). ABCA1 
is a cell membrane protein that transfers cholesterol and phospholipids outside of the cell to lipid 
poor proteins to be returned to the liver for catabolism (33). Reverse cholesterol transport occurs 
when free cholesterol inside the cell is transported outside through an ATP-binding cassette, sub-
family A protein (ABC1, ABC1, ABCA1) and interacts with APOA1, part of the HDL molecule 
that transports cholesterol to the liver (34). This directly influences lipid raft content in the 
membrane by decreasing cholesterol availability in the cell (33). A lipid raft is an area of the host 
membrane that contains high cholesterol and sphingolipid content, and is involved in signal 
transduction, and endocytosis (2). They are required at multiple points in the viral life cycle and 
server as docking sites for entry receptors and anchor viral glycoproteins during assembly (2). HIV 
trans infection is a major contributor of viral persistence during antiretroviral therapy (ART) and 
allows the virus to pass through an virological synapse between cells, bypassing antiretroviral drug 
effects that target receptor binding, integration and membrane fusion (32).  
It has previously been shown that ex vivo derived APC from progressors (PR) can still mediate 
HIV trans infection of CD4+ T cells while under virus suppressive ART, and that NP were still 
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unable to trans infect CD4+ T cells (Figure 4) (32). These data show that the virus can surpass 
antiviral drug effects and suggest an important role for APC-mediated trans infection in the 
maintenance of viral reservoirs and persistence during ART therapy. Understanding the ability of 
NP to control HIV disease progression could lead to the development of novel therapeutic 
strategies and vaccines. The following study aims to further characterize the APC cholesterol 
pathways involved in the inhibition of trans infection in NP through the identification of 
circulating biomarkers and genotypic characteristics that directly influence cholesterol metabolism 
and homeostasis. 
 
 
Figure 2. APC from NP do not Medicate HIV Trans Infection 
Trans infection results of autologous CD4+ T cells. APC mediated trans infection:  APC from seronegative donors 
were pulsed with HIVBal at sub-infectious dose, mixed with autologous CD4+T cells at 1:10 ratio and co-cultured 
for up to 16 days. Co-cultures supernatants were sampled at 4, 8, 12 and 16 days and HIVp24 was measured by 
ELISA Rappociolo, G. et al. Mbio 2014, DeLucia D. et al J.Virol 2018). 
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Figure 3. Membrane Lipid Rafts in NP vs PR MØ 
Images of NP and PR macrophages labeled with CTx-B to detect lipid rafts and analyzed by Millipore Image Stream 
(DeLucia D. et al J.Virology 2018). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 Trans Infection Results of Autologous CD4 + T cells in ART Treated Individuals 
B cells and DC derived from participants under suppressive ART were loaded with HIVBal and co-cultured with 
autologous CD4+ T cells for 12 days. CD4+ T cells were infected with HIV in cis. Supernatants were collected at 
the indicated time points and tested for HIV Gag p24. Data are mean values ±SE; n=10 experiments (Rappocciolo 
G. et al. Open Forum Infectious Diseases, 2019). 
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1.4 Cholesterol Regulation and HIV Progression  
Infection with HIV and treatment with ART therapy has been linked to differences in lipid 
concentrations, including higher serum  levels of low density lipoprotein (LDL), triglycerides and 
total cholesterol and lower levels of high density lipoprotein (HDL) (35). Lower levels of HDL 
have been linked to greater risk of atherosclerosis. HDL removes atherogenic lipids from 
atherosclerotic plaques to be cleared by the liver and this process is impaired during chronic 
inflammation (35). Macrophages in the vascular wall move lipids into HDL or APOA1 for reverse 
cholesterol efflux through ATP-binding cassette transporters and initiates reverse cholesterol 
transport through ABCA-1. ABCA-1 in human macrophages are the major cholesterol transporter, 
interacting with lipid-poor APOA1 to move cholesterol out of the cell (36).  
The capacity of HDL to remove cholesterol from macrophages is inversely correlated with 
coronary heart disease severity, and that increased HDL levels is a protective factor in 
atherosclerosis (37). It has also been shown that total cholesterol efflux was reduced by 12% in 
HIV infected individuals and the ability of ABCA-1-dependent cholesterol efflux is reduced by 
almost 30% (36). HIV infected individuals, in addition to having lower cholesterol efflux rates, 
are known to have reduced ability of whole plasma to remove cholesterol macrophages compared 
to the general population (36). This contributes to the lipid dysregulation problems they 
experience. Because of this need to be on lipid lowering medications even while on ART, as 
problems still persist while on therapy (38). It is currently not known if HIV NP have higher rates 
of cholesterol efflux than progressors or the general population. 
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1.4.1 Single Nucleotide Polymorphism Affecting Cholesterol Efflux 
It has been established that genetic factors contribute to variability in plasma HDL levels 
and account for approximately 40%-60% of that variation (39). Several genetic variants of genes 
involved in cholesterol biogenesis and maturation have also been identified: ABCA1, APOA1, 
ABCG1, APOAII, CETP and LIPC.  In a study by Villard et.al., the capacity of whole-plasma to 
mediate cholesterol efflux from macrophages was measured in 846 people (450 men and 496 
women). It was determined that rs17231506 (CETP c.-1337 C>T), rs2230806 (ABCA1 p.R219K), 
rs1799837 (APOA1 c.-75 G>A), rs5086 (APOAII c.-265 T>C), and rs1800588 (LIPC c.-514 C>T) 
single nucleotide polymorphisms (SNPs) significantly modulate the capacity of plasma to mediate 
cholesterol efflux from human macrophages and this was sex-dependent. It was estimated that 
these SNPs represented approximately 6% of total plasma efflux and that genetic plasma efflux 
capacity was a better predictor of macrophage cholesterol removal than plasma HDL levels. 
In women the APOA1 c.-75 G>A and the LIPC c.-514 C>T variants were determined to 
mediate cholesterol efflux, but in men the ABCA1 p.R219K and the APOAII c.-265 T>C SNPs 
were more prominent. Other data has shown that these genes are regulated by sex hormones, which 
may contribute to differences in transcription between genders (39). The rs1800588 (LIPC c.–514 
C>T) SNP is located in the hepatic lipase gene promoter and is associated with variation in plasma 
HDL levels and size, with the T variant associated with higher HDL levels. The rs2230806 
(ABCA1 p.R219K) SNP is located on the ABCA1 gene and is associated with higher HDL levels. 
The rs708272 (CETP TaqIB) SNP is located in the intron of the CETP gene and corresponds to 
higher HDL levels and particle size. rs5082 (APOAII c.–265 T>C) is a SNP in the APOAII gene 
that correlates to significantly higher efflux capacity. rs1799837 (APOA1 c.–75 G>A) is a SNP 
on the APOAI gene and correlates to higher plasma HDL.  
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1.5 Circulating Factors with Antiviral Properties 
1.5.1 Eicosanoids 
Eicosanoids are enzymatically generated oxidation products of arachidonic acid and related 
polyunsaturated fatty acids (PUFAs) produced by cyclooxygenase (COX), lipoxygenase (LOX), 
and cytochrome P450 (CYP) enzymes, and are known to regulate processes related to infection,  
inflammation and homeostatic functions (40). They have been found to be implicated in vascular 
permeability, platelet aggregation and have roles in autoimmunity, HIV, and cancer, as well as 
having pro-inflammatory and anti-inflammatory roles in immune regulation (41). 
1.5.1.1 5-oxo-Eicosatetraenoic Acid 
Arachidonic acid metabolite 5-oxo-eicosatetraenoic acid (5-oxo-ETE) is an formed by 5-
hydroxyeicosanoid dehydrogenase (5-HEDH) oxidation of 5-HETE (5S-hydroxy-eicosatetraenoic 
acid) (42). This molecule serves as a chemoattractant for eosinophils, neutrophils, monocytes and 
basophils, and regulates a variety of cellular process including actin polymerization, integrin 
expression, degranulation, and transport of calcium (43). NADP+ is required to synthesize 5-oxo-
ETE and can be stimulated by oxidative stress and the respiratory burst. It is regulated by the OXE 
receptor, a G-protein receptor, that is expressed at high levels in eosinophils, its primary target; 
implicating that it may have a role in asthma and allergy development (42). 5-oxo-ETE activates 
peroxisome proliferator-activated receptor gamma (PPAR) and is a chemoattractant, acting in a 
paracrine and autocrine manner as a signaling metabolite. PPAR activation increases transcription 
of the cholesterol transporter ABCA1, which in turn increases cholesterol transport out of the cell 
(44). 
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1.5.2 Oxysterols 
Oxysterols are a family of cholesterol oxidation derivatives that contain a hydroxyl, 
epoxide or ketone group in the sterol nucleus or a hydroxyl group in the side chain, and are derived 
from enzymatic or non-enzymatic activity on cholesterol (45). Multiple side-chain oxysterols 
(24OH, 25OH, 27OH) have been known to activate nuclear receptors such as liver-X-receptors 
(LXRs), retinoid X receptors (RXRs) and oestrogen receptors that activate transcription factors 
with key regulatory functions (46, 47). Many of these oxysterols have been known to block 
infection of many viruses by altering the cellular membrane, inhibiting viral entry, fusion and 
budding (48). 
1.5.2.1 25-Hydroxycholesterol 
The metabolite 25-Hydroxycholesterol (25HC) has broad antiviral activity on enveloped 
and non-enveloped viruses. 25HC is derived from cholesterol by the action of  Ch25h, an enzyme 
that hydroxylates cholesterol at the 25 position, and has been identified as an antiviral interferon-
stimulated gene (ISG) (48, 49). Ch25h is expressed strongly in myeloid cells including 
macrophages and dendritic cells in response to toll-like receptor ligands (TLR) and IFN which 
causes a decrease of cellular cholesterol through regulation of sterol-responsive element binding 
proteins (SREBP) and nuclear receptors (47). It has been shown that 25HC inhibits viral entry and 
fusion of many viruses, including HIV, Ebola, HSV, Dengue, RVF and many more (48). It is 
known that oxysterols such as 25HC regulate cholesterol homeostasis and make alterations to 
cholesterol in the cellular membrane affecting viral fusion and entry (50). The effects of this 
molecule on lipid rafts required for trans infection remain unclear. 
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2.0 Statement of Project and Specific Aims 
The aim of this study is to determine differences in cholesterol biogenesis and metabolism 
in NP vs PR and whether those differences translate to the inability of NP to trans infect CD4+ T 
cells. Cholesterol content of the cell is very important to the virus at various stages in its replication 
cycle and understanding these differences between NP and PR could translate to new therapeutic 
targets of the HIV reservoir, which is still active during ART therapy. We believe that there are 
differing cholesterol biomarkers between NP and PR, and these have not been well defined. We 
aimed to study cholesterol differences and reverse transport outside of the cell. We also aimed to 
translate these differences into genetic polymorphism between NP and PR that could also account 
for some of these differences.  
2.1 Aim 1: Determination of Cholesterol Efflux Capacity of Plasma From Male and Female 
NP and PR and Identification of Circulating Biomarkers of HIV Disease Nonprogression 
that Serve as Natural Ligands that Control ABCA-1 Activity and Link to the Inability of 
APC to Trans Infect CD4+ T Cells. 
Hypothesis: We hypothesized higher rates of cholesterol efflux from plasma of NP in both 
males and females and propose the identification of circulating biomarkers that serve as natural 
ligands that control ABCA-1 activity and link to the inability of APC to trans infect autologous 
CD4+ T cells. It has been shown that APC from NP are incapable of trans infecting CD4+ T cells, 
and this has been associated with altered cholesterol metabolism, disruption of lipid rafts and lower 
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cholesterol content in the cell membrane. It is also known that plasma cholesterol efflux capacity 
from THP-1 macrophages is lower in HIV-infected individuals (36). I predict that cholesterol 
efflux is higher in NP than PR. 
2.2 Aim 2: Correlation of Genetic Polymorphism with NP Phenotype in Male and Female 
Individuals. 
Hypothesis: We hypothesize that host genetic factors contribute to cell cholesterol 
homeostasis and metabolism and that these may differ between male and female NP. In a study by 
Villard et al. a series of SNPs were examined that have been implicated in cholesterol efflux 
capacity in male donors: rs17231506 (CETP c.– 1337 C>T), rs2230806 (ABCA1 p.R219K), 
rs1799837 (APOA1 c.–75 G>A), rs5086 (APOAII c.–265 T>C), and rs1800588 (LIPC c.–514 
C>T) (3). We have found that the rs5082, located in the APOAII gene, is significantly associated 
with the NP phenotype (p=0.0003) in male donors. In this study we will extend these findings to 
an additional 50 male samples from the MACS cohort that have recently been added and to 75 
female samples recently received from the WIHS cohort. 
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3.0 Materials and Methods 
3.1 Biosafety  
All experiments using live HIV-1 virus were performed in a biosafety level 2 plus (BSL2+) 
laboratory in the Graduate School of Public health at the University of Pittsburgh. Protective 
gowns and double-layer latex gloves were worn when working with live virus under a biosafety 
level 2 plus hood. All laboratory personnel were trained in sterile technique as well as working 
with infectious virus prior to being able to work independently with the HIV-1 virus.  
3.2 Cohorts and Samples 
Samples were received from the Multicenter Aids Cohort (MACS) participants (men who 
have sex with men) who are HIV-infected nonprogressors (NP), progressors (PR) and seronegative 
(SN). Samples were also received from the Women’s Interagency HIV Study (WIHS). In both of 
these cohorts, infected samples were matched to controls by age and race in sets of 3: 1 PR, 1 NP 
and 1 SN. Samples were all ART naïve and not on lipid lowering medications. The Multicenter 
AIDS Cohort Study (MACS), is an ongoing prospective cohort study of the natural and treated 
history of HIV/AIDS in men who report sex with men (51, 52) Participants were recruited from 
four U.S. metropolitan areas (Baltimore/Washington, Chicago, Los Angeles, and Pittsburgh), and 
study visits have been held at 6-month intervals beginning in 1983 
(www.statepi.jhsph.edu/macs/macs.html).  A total of 7,350 men have been enrolled in the MACS. 
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The WIHS  cohort sites were established in 1993 in Brooklyn, NY; the Bronx/Manhattan, NY; 
Washington, DC; Chicago, IL; San Francisco, CA; and Los Angeles, CA. Four southern sites were 
added in 2013: Chapel Hill, NC; Atlanta, GA; Birmingham, AL/Jackson, MS; and Miami, FL.  
The cohort enrolled   4982 women (53). 
At each semi-annual study visit, participants underwent standardized interviews, physical 
examinations and a blood draw. The institutional review boards of each center approved the study 
protocol and all participants gave informed consent.  
3.3 In vitro Assays 
3.3.1 Cell Culture and Activation 
3.3.1.1 B Lymphocytes 
CD19+ B Lymphocytes were separated from PBMC from SN donors using MACS 
microbead magnetic separation (Miltenyi Biotech) and activated for 2 days with IL-4 (R&D 
Systems) and CD-40 ligand (Enzo Life Sciences) in R10 medium at 1 million cells/mL prior to 
trans infection assay. R10 medium consisted of RPMI, 10% FBS and 25mM HEPES.  
3.3.1.2 CD4+ T lymphocytes 
CD4+ T cells were separated from PBMC from a SN donor using MACs magnetic bead 
separation (Miltenyi Biotech) and activated for 2 days with phytohemagglutinin P (PHA) (Sigma) 
and IL-2 (Roche) at 2 million cells/mL in RPMI/20% FBS/25mM HEPES prior to trans infection 
assay. 
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3.3.2 APC Mediated Trans Infection Assay 
R-tropic HIVBal purified from PM1 cells (obtained through the Aids Reagent Program, 
Division of AIDS, NIAID, NIH Dr. Marvin Reitz) was used for cis and trans infection 
experiments. Virus stock titration and experimental HIV-1- Gag p24 measurements were acquired 
by ELISA using the HIV-1 p24 Antigen Capture Immunoassay kit (SAIC-Frederick) per the 
manufacturer’s instructions (54). Activated B lymphocytes (1x106) were incubated with HIV-1 at 
a sub infectious dose (m.o.i. of 10-3) at 37°C for 2 h. HIV-1-infected B cells were washed three 
times with R10 medium and incubated with activated, autologous CD4+ T cells at a 1:10 ratio. As 
a control, CD4+ were cis infected with HIV-1 at an m.o.i. of 10–1. Supernatants from the trans and 
cis cultures were sampled every 4 days and tested for HIV-1 Gag p24 by ELISA. 
3.3.3 Bioactive Fatty Acid Screen  
Bioactive fatty acid analysis was conducted on plasma from HIV infected nonprogressors 
(NP), progressors (PR) and seronegatives (SN) in collaboration with the University of Pittsburgh 
lipidomic Core by LC-MS/MS. Plasma samples were mixed with 2 parts chloroform and 1-part 
methanol and centrifuged at 2800xg for 10 minutes. The organic phase was transferred to a new 
vial and the internal standards 5-oxoETE-d7 (2 µg/mL) and 15-HETE-d6 (1 µg/mL) were added 
before drying under N2. Samples were reconstituted in 100 µL MeOH and 10 µL was injected onto 
a Luna C18(2) reversed phase column (Phenomenex, Torrence, CA) for separation. Bioactive fatty 
acids were separated and analyzed using a Sciex Exion UHPLC coupled to a 6500+ QTrap mass 
spectrometer in negative ion mode. Bioactive fatty acids were reported as a ratio of peak area of 
analyte/peak area of the internal standard.  
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3.3.4 Cholesterol Efflux Assay  
Plasma was assessed for cholesterol efflux capacity using a commercially available kit: 
Cholesterol Efflux Fluorometric Assay Kit (BioVision). Macrophage cell line THP-1 cells were 
loaded with labelled cholesterol and exposed to plasma of NP or PR for four hours. Efflux was 
measured by fluorescence intensity according to manufacturer’s instructions.  
3.3.5 25-Hydroxycholesterol ELISA  
PR and NP were measured for serum concentration of metabolite 25HC using a 
manufactured 25-HC ELISA kit (MyBioSource). The assay uses the competitive enzyme 
immunoassay containing a polyclonal anti-20S-PSM antibody and an 20S-PSM-HRP conjugate. 
The assay sample and buffer are incubated together with conjugate in pre-coated plate for one 
hour. After the incubation period, the wells are washed five times and incubated with a substrate 
for HRP enzyme. Intensity was measured at 450nm.  
3.3.6 DNA Extraction Assay  
DNA of NP, PR and SN was extracted from PBMC pellets using the Qiagen DNA Easy 
Core Blood Kit A per manufacturer’s instructions. 
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3.3.7 TaqMan SNP Detection Assay 
TaqMan assays were performed for SNPs identified by Villard et.al. Probes were designed 
to amplify 100-150 base pair regions containing the SNP and the wild type for SNPs identified by 
Villard et.al. with a different fluorochrome attached to each probe. Fluorescence was analyzed 
using PCR genotyping assays to determine hetero and homozygous samples in NP and PR cohorts. 
3.3.8 Millipore Image Cytometry 
B cells were activated for two days in charcoal-stripped FBS with IL-4 and CD-40L, treated 
for 4 and 24 hours with or without 25HC and subsequently stained using the Vybrant Alexa Fluor 
488 lipid raft labeling kit (Molecular Probes) and analyzed by Millipore Image Cytometry for 
membrane intensity.  
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4.0 Results 
4.1 Aim 1: Determination of Cholesterol Efflux Capacity of Plasma from Male and Female 
NP and PR, and Identification of Circulating Biomarkers of HIV Disease Nonprogression 
that Serve as Natural Ligands that Control ABCA-1 activity and Link to the Inability of 
APC to trans infect CD4+ T cells. 
4.1.1 Determination of Cholesterol Efflux Capacity of Plasma from Male and Female NP 
and PR 
It has been shown that APC from NP are incapable of trans infecting CD4+ T cells, and 
this has been associated with altered cholesterol metabolism and disruption of lipid rafts and lower 
cholesterol content in the cell membrane (55). It has also known that plasma cholesterol efflux 
capacity from THP-1 macrophages is lower in HIV-infected individuals (36). We hypothesized 
that cholesterol efflux could be higher in NP than PR. Plasma was tested from 60 male NP and 
matched PR and SN controls to determine the rate of cholesterol efflux from macrophage cell line 
THP-1.  Our data show that plasma from NP had higher cholesterol efflux than from PR 
(unpublished). In this study plasma from female NPs will show a similar pattern.  As shown in 
Figure 5, plasma from NP participants induce higher cholesterol efflux compared to PR and SN 
donors.  Our preliminary data shows cholesterol efflux in NP and PR by gender in our MACS and 
WIHS cohorts follows a similar trend, with NP having a significant increase in cholesterol efflux 
compared to PR in both cohorts (p = 0.0001). 
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Figure 5. Plasma from NP Induces Higher Cholesterol than PR 
Macrophage cell line THP-1 were loaded with labelled cholesterol and exposed to plasma of NP or PR for four 
hours, using a commercially available kit (Biovision) per manufacturer’s instructions. Efflux was measured by 
fluorence intensity at 450 nm. MACS N= 25 NP, PR, SN; WIHS NP = 20, PR = 22, SN = 24. Significance was 
calculated using a two-sided T test. Bars represent mean±SE. 
4.1.2 Bioactive Fatty Acid Screen 
To determine if circulating factors were responsible for higher efflux activity, a bioactive 
fatty acid screen was performed with the Health Sciences and Metabolomics Lipidomic core at the 
University of Pittsburgh on a subset of NP and PR samples. Analysis by liquid-chromatography-
mass spectrometry identified metabolites present at a higher level in a number of NP than PR, 
specifically 5-oxo-eicosatetraenoic acid (5-oxo-ETE) (Figure 6). 5-oxo-ETE is derived from 
lipoxygenase activity on arachidonic acid from membrane sphingolipids produced by DC and B 
lymphocytes, macrophages and eosinophils (43). The first three cell types mediate CD4+ trans 
infection. 5-oxo-ETE is a chemoattractant and acts in a paracrine and autocrine manner as a 
signaling metabolite, binding and activating nuclear receptor PPAR and inducing cholesterol 
efflux by increasing transcription of the cholesterol transporter ABCA1. Although the overall 
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increase in 5-oxo-ETE levels were significantly increased, not all of the NP samples show a 
difference compared to PR. This increase seems to be a trait that only a percentage of NP will 
have. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Fatty Acid Analysis of Plasma from NP Contains Higher Levels of 5-Oxo-ETD than PR 
Bioactive Fatty Acid screen analysis was conducted on plasma from HIV infected NP and progressors (PR) in 
collaboration with the lipidomic Core by LC-MS. Plasma from NP was found to have increased levels of cholesterol 
metabolite 5-oxo-ETE compared to PR.  PR N = 14; NP N = 23. Significance was calculated using a two-sided T 
test. Bars represent mean±SE. 
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4.1.3 APC Mediated Trans Infection in Presence of 5-oxo-Eicosatetraenoic acid (5-oxo-
ETE) 
To determine if treatment with 5-Oxo-ETE would affect trans infection, a trans infection 
assay was performed. B and T cells were treated with 5µM 5-Oxo-ETE and supernatants were 
taken at days 4, 8 and 12. HIV-1 p24 capsid protein concentration in cell cultures supernatants was 
measured by ELISA. Data show that 5-oxo-ETE treatment of APC reduces the efficiency of HIV 
trans infection of CD4+T cells, but was not statistically significant (Figure 7). We hypothesize 
that this molecule is limiting levels of trans infection of APC to CD4+ T cells by altering rate of 
cholesterol efflux from APCs. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. APC Mediated Trans Infection in Presecne of 5-oxo-ETE 
APC from seronegative donors were pulsed with HIVBal at sub-infectious dose, mixed with autologous CD4+T 
cells at 1:10 ratio and co-cultured for 12 days with or without 5-oxo-ETE at 5µM. Co-culture supernatants were 
sampled at 4, 8, 12 days and HIVp24 was measured by ELISA.  N=3 Bars represent mean±SE. 
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4.1.4 Detection of 25-Hydroxycholesterol in Serum of NP vs PR 
Another signaling metabolite known to modulate immune cells activity is 25-
Hydroxycholesterol (25HC) (56), which has been shown to have broad antiviral activities against 
other viruses. It plays multiple roles in lipid biosynthesis and immunity and is able to modulate 
cholesterol metabolism by promoting ABCA1 expression, resulting in reduced cellular-associate 
cholesterol. It also interferes with virus-cell membrane fusion and reduces inflammatory factors 
and cytokines (56). We have tested the effects of 25HC in plasma of NP and PR using an Elisa kit 
purchased from Biosource (Figure 8) Preliminary data show that NP have higher levels of 25HC 
than PR and SN, but given the limited number of participant tested further testing of samples is 
needed to determine its significance. 
 
 
 
 
 
 
 
 
 
Figure 8. Preliminary Data pf 25HC Elisa Assay 
Plasma of NP, PR and SN were tested using an anti-25HC Elisa kit purchased from Biosource. N=24. 
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4.1.5 APC-Mediated Trans Infection in the Presence of 25-Hydroxycholesterol 
In order to determine the effect of 25HC on HIV trans infection, we performed a trans 
infection assay (Figure 9) in the presence of this bioactive molecule. Treatment of B cells with 
25HC at 0.3µg/mL in culture strongly inhibited HIV trans infection compared to untreated cells. 
Trans infection efficiency was also decreased when cells were pre-treated with 25HC 12 hours 
prior to infection at 0.3µg/mL. In the pre-treatment, 25HC was removed from culture prior to 
infection with HIV-1. 
   
 
 
 
 
 
 
 
 
 
 
Figure 9. Treatment with 25HC Inhibits B-cell Mediated Trans Infection 
APC from seronegative donors were pulsed with HIVBal at sub-infectious dose, mixed with autologous CD4+T 
cells at 1:10 ratio and co-cultured for up to 12 days with or without 25HC at .3µg/m. Co-culture supernatants were 
sampled at 4, 8 and 12 days and HIVp24 was measured by ELISA. Significance was calculated using a two-way 
Anova test **, p < .008. ***, p < .0005. n = 3. Bars represent mean±SE. 
 
n = 3 
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4.1.6 Dose Response to Pre-Treatment of 25HC in B Cell Mediated Trans Infection. 
In order to determine the effect of different concentrations of 25HC on B cell mediated 
trans infection, a we performed a dose response experiment. B cells were treated with various 
concentrations of 25HC 12 hours prior to infection and then removed from the media prior to 
infection. Our data show that pre-treatment with 25HC does not significantly affect trans infection 
(Figure 10). 
 
Figure 10. Dose Response to Pre-Treatment with 25HC 
APC from seronegative donors were treated for 12 hours before infection with 25HC at varying concentrations, 
pulsed with HIVBal at sub-infectious dose, mixed with autologous CD4+T cells at 1:10 ratio and co-cultured for up 
to 12 days. Co-culture supernatants were sampled at 4, 8 and 12 days and HIVp24 was measured by ELISA. 
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4.1.7 25HC Reduces Membrane Associated Lipid Rafts  
The signaling metabolite 25HC has been shown to inhibit viral entry and membrane fusion 
by altering cholesterol in cellular membrane. To determine the effect of this molecule on cellular 
membrane lipid rafts, B cells were treated for 4 and 24 hours at 0.3 ug/mL and were exposed to 
CTx-B for lipid raft labeling and analyzed by flow cytometry using Millipore Image Stream. 
TO901317 was used as a control because it is a Liver X Receptor agonist that plays a key role in 
reverse cholesterol transport by increasing cholesterol efflux and reverse cholesterol transport 
through HDL. LXR activation does not interfere with CD40L and IL-4 mediated B cell activation 
and proliferation (55). Our data show that treatment with 25HC reduces membrane intensity, 
lowering lipid raft content in B cells (Figure 11). Images are representative of treated and untreated 
populations. 
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Figure 11. Treatment with 25HC Reduces Membrane Associated Lipid Rafts 
B cells were treated with 25HC for 4 and 24 hours in charcoal-stripped R10, stained for Ctx-B lipid rafts and flow 
cytometry was performed using Millipore Image Stream. N = 3. Bars represent mean±SE. Representative images of 
B cells labeled with CTx-B to detect lipid rafts and analyzed by Millipore Image Stream. Significance was 
calculated using a two-sided T test. Bars represent mean±SE. 
 
Untreated B cell 25HC Treated B cell 
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4.2 AIM 2: Identification of genetic factors contributing to the NP genotype and phenotype. 
In a study by Villard et al. a series of SNPs were examined that have been implicated in 
cholesterol efflux capacity in male donors: rs17231506 (CETP c.– 1337 C>T), rs2230806 
(ABCA1 p.R219K), rs1799837 (APOA1 c.–75 G>A), rs5086 (APOAII c.–265 T>C), and 
rs1800588 (LIPC c.–514 C>T) (39). Previously we have found that the SNP rs5082, located in the 
APOAII gene, is significantly associated with the NP phenotype (p=0.0003) in male donors from 
the MACS. In this study we extended this analysis to 50 additional male samples from the MACS 
cohort and 75 female samples received from the WIHS cohort. DNA was extracted from PBMC 
cell pellets using the Qiagen DNA Easy Core Blood Kit A. SNP genotyping assays were then 
performed to identify the presence of SNPs identified by Villard et al. as modulators of cholesterol 
efflux using PCR.  
We found SNP rs1800588 to be significantly associated with the NP cohort (p = 0.0003), 
which had not previously been significant when tested in a smaller cohort. This SNP is a mutation 
in the Hepatic Lipase (LIPC) gene promoter. LIPC plays a key role in reverse cholesterol transport, 
metabolism of several lipoproteins and is associated with higher serum high density lipoprotein 
(HDL) levels. It was shown to be a major determinant of cholesterol efflux in women by Villard 
et.al, but we found it to be very significant in the male NP cohort samples. The rs5082 SNP was 
still significantly associated with the NP phenotype, although at a higher p-value (p = 0.02). As 
stated above, this is a mutation in the promoter of the APOAII gene which decreases its 
transcription and was identified to be associated with significantly higher cholesterol efflux in men 
by Villard et.al (39). The remaining SNPs were not found to be significant in our cohort. SNPs 
and corresponding P-values are listed in Figure 12.  
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Figure 12. Single Nucleotide Polymorphism in NP Cohort 
DNA was extracted from PBMC cell pellets using Qiagen Puregene Blood Core Kit B according to manufacturer 
instructions. PCR Genotyping Assays were then performed to determine heterozygous and homozygous allele 
frequencing. P-values were calculated using an odds ratio. N=50. 
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5.0 Discussion 
Currently there are 1.1 million people living with HIV in the U.S., and there are 
approximately 38,500 new infections each year (8). Deaths from the virus have been greatly 
reduced with the invention of ART therapy, but this has been associated with metabolic side 
effects, including dyslipidemia, hypertriglyceridemia, hypercholesterolemia and diabetes (57). For 
this reason levels of HIV patients need to be closely monitored and many people have to take lipid 
lowering medications to protect against coronary heart disease and other conditions.  In this study, 
we aimed to identify circulating biomarkers of HIV nonprogression that modulate cholesterol 
metabolism for alternative therapeutics and vaccines. 
HIV nonprogressors comprise a small percentage of individuals who are able to control 
HIV infection for many years without therapeutic intervention. They have been characterized 
based on their HLA class I alleles, CCR5-Delta32 mutation, viral attenuation and many other 
factors, but these do not explain all of the known NPs. We have found that the APC of NP are 
unable to trans infect CD4+ T cells and this has been linked to differences in cholesterol 
metabolism between NP and PR (32).  In our current cohort, the inability of APC of NP to trans 
infect CD4+ T cells is present in every NP we have studied. Previously it has been shown that HIV 
infected individuals have lower cholesterol efflux than the normal population and have lower 
levels of HDL and increased risk of atherosclerosis (35, 36). In our study, we found that plasma 
of NP had higher cholesterol efflux from macrophages than PR in both the MACS and WIHS 
cohorts (Figure 5) (p = 0.0001). This implies that plasma of male and female NP have higher levels 
of reverse cholesterol transport out of the cell. 
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We performed a bioactive fatty acid screen was on plasma of NP and PR to identify 
potential metabolites involved in cholesterol metabolism in NP compared to PR by LC-MS/MS 
(Figure 6). A molecule 5-oxo-eicosatetraenoic acid (5-oxo-ETE) was found to be significantly 
increased in NP and PR. 5-oxo-ETE is derived from lipoxygenase activity on arachidonic acid 
from membrane sphingolipids produced by DC and B lymphocytes, macrophages and eosinophils. 
The first three cell types mediate CD4+ trans infection. This molecule serves as a chemoattractant 
for eosinophils, neutrophils, monocytes and basophils, and regulates a variety of cellular processes 
including actin polymerization, integrin expression, degranulation, and transport of calcium (43). 
5-oxo-ETE is a chemoattractant and acts in a paracrine and autocrine manner as a signaling 
metabolite, binding and activating nuclear receptor PPAR and inducing cholesterol efflux by 
increasing transcription of the cholesterol transporter ABCA1.  
When B and T cells were treated with 5µM 5-oxo-ETE and a trans infection assay was 
performed, efficiency was reduced but this was not statistically significant (Figure 7). We plan to 
perform this assay at higher concentrations with the drug to determine toxicity levels. If non-toxic 
to at higher concentrations, more studies should be performed to understand it’s potential as a 
therapeutic target in the control of HIV. In the lipidomic screen we did notice that only some NP 
had higher concentrations of this metabolite (Figure 6). This could be  related to  nonprogression 
in only some individuals in our cohort and since it is  is not ubiquitously found at higher levels in 
all NP. 
25-Hydroxycholesterol is a potent molecule that had been featured recently in scientific 
literature as an antiviral, and we wanted to investigate the effect of it on APC-mediated trans 
infection. It is known to play multiple roles in lipid biosynthesis and immunity, and modulates 
cholesterol metabolism by altering cholesterol content in the cellular membrane, interfering with 
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virus-cell membrane fusion and reduces inflammatory factors and cytokines (48). We tested the 
ccontent of 25HC in NP and PR using an Elisa kit purchased from Biosource. More samples need 
to be tested to determine significance, but our preliminary data show that NP may have higher 
levels of 25HC which may alter cholesterol metabolism and protect against viral infection by 
interfering with membrane fusion during formation of the infectious   
To determine the effect of 25HC on trans infection, B cells were treated with .3 ug/mL and 
in culture for up to 12 days or pre-treated for 12 hours and removed from the culture media prior 
to infection. When 25HC was left in culture, it strongly inhibited trans infection (Figure 9). When 
25HC was pre-treated and then removed from culture, it reduced efficiency, but this was not 
significant. We hypothesize that 25HC is continuously altering cholesterol in the cellular 
membrane and interfering with membrane fusion and the ability of APC to trans infect CD4+ T 
cells. We speculate that it is likely that when left in culture, 25HC is modulating cholesterol in the 
cellular membrane and severely limiting the ability to form the infectious synapse in trans 
infection. Because this molecule was so effective, we believe it may be useful as a potential 
addition to ART therapy.  
We were curious to see if altering the concentration of the pre-treatment in the trans 
infection assay would create a dose response to the drug, so three concentrations were tested. Cells 
were treated with varying concentrations of the drug for 12 hours prior to infection. The drug was 
then washed from the media and a trans infection assay was performed. The results of the 
experiment were not significant. A benefit of this may have been to use this effectively in a PREP 
treatment for HIV. We speculate that 25HC is most effective when left in culture, because it is 
continuously making changes to the cellular membrane. The membrane is very fluid, and removing 
25HC may inhibit it from making alterations to new cholesterol being added. 
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In other viruses, 25HC alters lipid raft formation in the cellular membrane. To confirm this 
in HIV, image cytometry was performed. B cells were treated with 25HC for 4 and 24 hours 
(Figure 10) and analyzed via Millipore Image Stream. Cells that were treated with 25HC for 24 
hours had lower, more diffuse florescence than cells that were untreated or treated with the 
TO901317 control. Our data show that 25HC is significantly limiting lipid raft formation, and this  
could  interfere with the ability of the virus to orchestrate trans infection and maintain the HIV 
reservoir under ART therapy. 
In a study by Villard et al. a series of SNPs were examined that have been implicated in 
cholesterol efflux capacity in male and female donors. It has been established that genetic factors 
contribute to variability in plasma HDL levels and account for approximately 40%-60% of that 
variation (39). Several genetic variants of genes involved in cholesterol biogenesis and maturation 
have also been identified: ABCA1, APOA1, ABCG1, APOAII, CETP and LIPC. Previously in 
our cohort we found one SNP to be significantly associated with being an NP. 50 new male samples 
from the MACS study were added, and we found two SNPs to be significantly associated with the 
NP cohort, rs1800588 (p = 0.0003) and rs5082 (p = 0.02) (Figure 11).  Our lab recently received 
75 new samples from the WIHS cohort, and plan to carry out the same analysis with these using 
Taq-Man Genotyping assays.  
The rs1800588 SNP is a mutation in the Hepatic Lipase (LIPC) gene promoter that plays a 
key role in reverse cholesterol transport, metabolism of several lipoproteins and is associated with 
higher serum high density lipoprotein (HDL) levels. It was shown to be a major determinant of 
cholesterol efflux in women by Villard et.al, but it was found to be very significant in our male 
NP cohort samples. Because this SNP is decreasing transcription of the LIPC gene, it is also 
decreasing the ability of hepatic lipase to bind HL, part of the HDL molecule, and this inhibits the 
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function of HDL. Higher serum HDL levels is a protective factor of atherosclerosis and is also 
likely to be protective many viruses by decreasing cholesterol availability in the cellular 
membrane. This SNP could be beneficial in HIV infection because of the increased transfer of 
cellular cholesterol to HDL for processing by the liver instead of remaining inside of the cell. 
The rs5082 is a mutation in the promoter of the APOAII gene which decreases its 
transcription and was identified to be associated with significantly higher cholesterol efflux in men 
by Villard et.al (39). APOAII is associated with higher serum LDL levels,  a contributing factor to 
atherosclerosis, and higher cellular associated cholesterol. This SNP is decreasing cellular 
associated cholesterol and ability of the virus to spread from cell to cell by limiting lipid raft 
formation. Both of the SNPs we found likely contribute a small amount to the overall capacity of 
NP and PR ability to trans infect.  
In this study we dove deeper into the differences in cholesterol metabolism between NP 
and PR, and found differing biomarkers and genetic polymorphism between the two groups. Even 
though we found some characteristics of the NP cohort  that can help explain their ability to control 
HIV infection, more studies are needed. Possible next steps in the project would be to expand the 
analysis of cholesterol and bioactive metabolites in NP vs PR through the lipidomic core. The test 
we performed was not designed to  detect oxysterols, and this was a type of metabolite we were 
interested in exploring deeper. We also wanted to try different APC, such as dendritic cells and 
macrophages,  for lipid rafts content and  to measure total cellular cholesterol as well in the 
presence of bioactive molecules identified through lipidomic analysis. Hopefully we will be able 
to understand the complete picture of what differentiates NP and PR, and this will lead us to new 
therapeutics that target the ability of HIV to spread, and to maintain the latent reservoir. 
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6.0 Supplementary Data 
6.1 Cellular Toxicity to 25-Hydroxycholesterol 
To determine cellar toxicity levels to 25HC, T and B cells were cultured separately with or 
without 25HC at .3µg/mL and viability was measured on day 4 using a hemocytometer. These data 
show that there is not difference in viability of cells treated at this concentration (Figure 13). 
 
Figure 13. Cellular Toxicity of 25 Hydroxycholesterol 
B and T cells were cultured with 25HC at 0.3µg/mL and counted using a hemocytometer to measure cellular 
viability on day 4. Significance was calculated using a Chi-Square test.. n = 3. Bars represent mean±SE. 
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